Navigation Links
NYU Cancer Institute researcher among first NIH EUREKA award recipients
Date:9/3/2008

New York City, NY September 3, 2008 - The National Institutes of Health (NIH) has awarded $42.2 million to fund 38 exceptionally innovative research projects that could have an extraordinarily significant impact on many areas of science. The grants, from a new program called EUREKA (for Exceptional, Unconventional Research Enabling Knowledge Acceleration), targets investigators who are testing novel, unconventional hypotheses or are pursuing major methodological or technical advances. Eureka researchers will receive direct costs of approximately $200,000 per year for up to four years.

Michelle Krogsgaard, Ph.D, assistant professor of pathology at the NYU Cancer Institute, is the first NYU School of Medicine recipient of the EUREKA award. In 2006, Dr. Krogsgaard joined NYU and her work has focused on the different signaling methods T-cells use in the contexts of cancer and autoimmune disease. The EUREKA award will allow Dr. Krogsgaard to explore the complex molecular mechanisms that govern the training and activation of immune cells; specifically, how intracellular signals are generated in T-cells, currently an immunological black box. Dr. Krogsgaard practices an interdisciplinary approach to her research, which incorporates cellular, chemical and structural biology techniques. Through this fresh perspective and multidisciplinary approach, Dr. Krogsgaard aims to build on her previous training to initiate a novel and risky approach to study mechanisms of T-cell signaling and to bolster her controversial hypothesis that structural changes in the receptor complex are important for T-cell signaling. This award will give her the freedom to explore innovative techniques and interdisciplinary approaches that would not be supported by an R01 award.

Using a combination of novel imaging and biophysical techniques, Dr. Krogsgaard investigates how one can manipulate signaling mechanisms in T-cells which could enhance the immune response in patients with HIV or cancer or diminish T-cell activation in patients with autoimmune disease.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. Blood fingerprints for cancer
2. Height linked to risk of prostate cancer development and progression
3. TGen and Washington University researchers discover new approach to treating endometrial cancer
4. Landmark study opens door to new cancer, aging treatments
5. Growth factor predicts poor outcome in breast cancer
6. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
7. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
8. Normalizing tumor vessels to improve cancer therapy
9. CSHL scientists identify new drug target against virulent type of breast cancer
10. Gene therapy anti-cancer research featured in Scientific American
11. Dense tissue promotes aggressive cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: